The present disclosure is in the field of pharmaceutical compositions suitable for the treatment of diseases in mammals. The disclosure provides novel compositions comprising non-pathogenic fecal microbes for treating irritable bowel syndrome and related diseases. The disclosure also provides methods for treating a subject with the compositions disclosed herein.
